Validating the Breathing Vigilance Questionnaire for use in dysfunctional breathing.


Journal

The European respiratory journal
ISSN: 1399-3003
Titre abrégé: Eur Respir J
Pays: England
ID NLM: 8803460

Informations de publication

Date de publication:
Jun 2023
Historique:
received: 19 07 2022
accepted: 24 03 2023
medline: 12 6 2023
pubmed: 7 4 2023
entrez: 6 4 2023
Statut: epublish

Résumé

Dysfunctional breathing is common among people with and without primary respiratory pathology. While anxiety can contribute to dysfunctional breathing, the underpinning mechanism is unclear. One explanation is that anxiety induces conscious, vigilant monitoring of breathing, disrupting "automatic" breathing mechanics. We validated a new tool that quantifies such breathing-related "vigilance": the Breathing Vigilance Questionnaire (Breathe-VQ). 323 healthy adults (mean (range) age 27.3 (18-71) years; 161 males) were analysed. We developed an initial Breathe-VQ (11 items, 1-5 Likert scale) based on the Pain Vigilance and Awareness Scale, using feedback from the target population and clinicians. At baseline, participants completed the Breathe-VQ, Nijmegen Questionnaire (NQ), State-Trait Anxiety Inventory form 2 and Movement-Specific Reinvestment Scale (assessing general conscious processing). 83 people repeated the Breathe-VQ 3 weeks later. Five items were removed based on item-level analysis. The resulting six-item Breathe-VQ questionnaire (score range 6-30) has excellent internal (α=0.892) and test-retest reliability (intraclass correlation 0.810), a minimal detectable change of 6.5 and no floor/ceiling effects. Validity was evidenced by significant positive correlations with trait anxiety and conscious processing scores (r=0.35-0.46). Participants at high risk of having dysfunctional breathing (NQ >23; n=76) had significantly higher Breathe-VQ score (mean±sd 19.1±5.0) than low-risk peers (n=225; mean±sd 13.8±5.4; p<0.001). In this "high risk of dysfunctional breathing" group, Breathe-VQ and NQ scores were significantly associated (p=0.005), even when controlling for risk factors ( The Breathe-VQ is a valid and reliable tool to measure breathing vigilance. High breathing vigilance may contribute to dysfunctional breathing and could represent a therapeutic target. Further research is warranted to test Breathe-VQ's prognostic value and assess intervention effects.

Sections du résumé

BACKGROUND BACKGROUND
Dysfunctional breathing is common among people with and without primary respiratory pathology. While anxiety can contribute to dysfunctional breathing, the underpinning mechanism is unclear. One explanation is that anxiety induces conscious, vigilant monitoring of breathing, disrupting "automatic" breathing mechanics. We validated a new tool that quantifies such breathing-related "vigilance": the Breathing Vigilance Questionnaire (Breathe-VQ).
METHODS METHODS
323 healthy adults (mean (range) age 27.3 (18-71) years; 161 males) were analysed. We developed an initial Breathe-VQ (11 items, 1-5 Likert scale) based on the Pain Vigilance and Awareness Scale, using feedback from the target population and clinicians. At baseline, participants completed the Breathe-VQ, Nijmegen Questionnaire (NQ), State-Trait Anxiety Inventory form 2 and Movement-Specific Reinvestment Scale (assessing general conscious processing). 83 people repeated the Breathe-VQ 3 weeks later.
RESULTS RESULTS
Five items were removed based on item-level analysis. The resulting six-item Breathe-VQ questionnaire (score range 6-30) has excellent internal (α=0.892) and test-retest reliability (intraclass correlation 0.810), a minimal detectable change of 6.5 and no floor/ceiling effects. Validity was evidenced by significant positive correlations with trait anxiety and conscious processing scores (r=0.35-0.46). Participants at high risk of having dysfunctional breathing (NQ >23; n=76) had significantly higher Breathe-VQ score (mean±sd 19.1±5.0) than low-risk peers (n=225; mean±sd 13.8±5.4; p<0.001). In this "high risk of dysfunctional breathing" group, Breathe-VQ and NQ scores were significantly associated (p=0.005), even when controlling for risk factors (
CONCLUSIONS CONCLUSIONS
The Breathe-VQ is a valid and reliable tool to measure breathing vigilance. High breathing vigilance may contribute to dysfunctional breathing and could represent a therapeutic target. Further research is warranted to test Breathe-VQ's prognostic value and assess intervention effects.

Identifiants

pubmed: 37024133
pii: 13993003.00031-2023
doi: 10.1183/13993003.00031-2023
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright ©The authors 2023. For reproduction rights and permissions contact permissions@ersnet.org.

Déclaration de conflit d'intérêts

Conflict of interest: The authors declare that they have no competing interests.

Auteurs

Jennifer Steinmann (J)

Guy's and St Thomas' NHS Foundation Trust, London, UK.
College of Health, Medicine and Life Sciences, Department of Health Sciences, Brunel University London, London, UK.
J. Steinmann and A. Lewis are joint first authors.

Adam Lewis (A)

College of Health, Medicine and Life Sciences, Department of Health Sciences, Brunel University London, London, UK.
Centre for Smart Technology Advancements for Health and Rehabilitation, Brunel University London, London, UK.
J. Steinmann and A. Lewis are joint first authors.

Toby J Ellmers (TJ)

Department of Brain Sciences, Imperial College London, London, UK.
Centre for Cognitive Neuroscience, Brunel University London, London, UK.

Mandy Jones (M)

College of Health, Medicine and Life Sciences, Department of Health Sciences, Brunel University London, London, UK.

Vicky MacBean (V)

College of Health, Medicine and Life Sciences, Department of Health Sciences, Brunel University London, London, UK.
Centre for Smart Technology Advancements for Health and Rehabilitation, Brunel University London, London, UK.

Elmar Kal (E)

College of Health, Medicine and Life Sciences, Department of Health Sciences, Brunel University London, London, UK elmar.kal@brunel.ac.uk.
Centre for Smart Technology Advancements for Health and Rehabilitation, Brunel University London, London, UK.
Centre for Cognitive Neuroscience, Brunel University London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH